Celltrion announced that Remsima SC, the only subcutaneous form of infliximab in the world, has achieved a record market share in Australia. In the first quarter of the year, Remsima SC secured a 20 percent market share, reflecting a significant increase since its introduction in 2021. The convenience of self-administration at home, particularly during the challenges of the COVID-19 pandemic, has been a key factor driving Remsima SC's popularity in Australia. To further improve accessibility, Celltrion has introduced a delivery service through which patients can receive the drug at their preferred location, catering to Australia's vast geography. In addition to the success of Remsima SC, Celltrion's cancer treatment trastuzumab and rituximab also maintained strong market leads in Australia. Celltrion attributed its robust growth to a tailored sales approach that involved engaging with local stakeholders through conferences and sharing clinical data. Looking ahead, Celltrion plans to introduce several new biosimilars, further expanding its market reach and transforming the lives of patients in Australia.